| |
Received by NCI in 2004 from NIH. The scid mutation has been transferred onto a diabetes-susceptible Non-Obese Diabetic background. Animals homozygous for the scid mutations experience a block in T and B-cell lymphocyte development. The multiple defects in immunity unique to this model provide an excellent system for reconstitution with human hematopoietic cells, resulting in exceptional models for HIV-1 research and gene therapy. The NOD scid is a useful model for cancer research due to increased tumor incidence, particularly lymphomas and thymic tumors. This strain is also a good model for diabetes and obesity research for Insulin-Dependent Diabetes Mellitus, Type I diabetes.
|
